{{ $DoctorName }} @if (isset(session()->get('doctor')['vCentralCode'])) {{ session()->get('doctor')['vCentralCode'] }} @endif
@if (isset(session()->get('doctor')['vCentralCode']))
Logout
@endif

{{ $ActivityTypeName }}

{{ $ActivityName }}

@csrf
@if (isset(session()->get('doctor')['vCentralCode']))
Back
@else
@endif

Survey Questionnaire Form

  1. Which of the following statements do you think is most related to Indian diabetic phenotype (Tick any one)? *

  2. Rate the following statements on the scale of 1 to 5 where 1 being the least and 5 being the most…*

  3. As diabetes is a cardiovascular risk equivalent in general - do you believe diabetes increases risk of Heart Failure manifold ? (Tick any one) *

  4. How do you compare risk of CKD as compared to Heart Failure in your diabetic patient population ? (Tick any one) *

  5. What % of your patients are on newer class of drugs – DPP4i, SGLT2i etc. - as a first line therapy post Metformin? (Tick any one) *

  6. What are the 3 top-most reasons for prescribing newer class of drug as first line therapy? *




  7. Which age group of patients will receive these newer class of drugs the most as first line therapy, post Metformin, in your clinical practice? (Tick any one) *

  8. Among the newer oral antidiabetic, do you consider SGLT2 inhibitors and DPP4 inhibitors as equally efficacious? *

  9. How do you find the tolerability of following drugs in your clinical practice? (Select any one)*
    10. Sitagliptin
    Dapagliflozin
  10. Rank the SGLT 2 inhibitors in terms of Glycemic control or efficacy. (From 1 to 4, 1 being the highest) *

  11. Rank the DPP4 inhibitors in terms of Glycemic control or efficacy. (From 1 to 4, 1 being the highest) *

  12. In patients uncontrolled on Metformin with moderately high HbA1c levels, which of the following class of drug would you like to initiate first? *

  13. In diabetes patient with established ASCVD or heart failure, which class of the drug will be preferred by you as a second line treatment? *

  14. In diabetes patients with CKD, which class of the drug will be preferred by you as a second line treatment? *

  15. In low risk diabetes patients (without HF/ASCVD or CKD), when there is a need to reduce the chances of hypoglycemia, which of the following class of drug would you prefer as a second line treatment? *

  16. Among elderly diabetic patients, which of the following class of drug would you prefer taking into consideration the safety aspects? *

  17. According to you, initial usage of SUs would be replaced by which class of drug? *

  18. Approximately what% of uncontrolled T2D patients do you feel the need for SGLT2i and DPP4i combination? *

  19. What percentage of your diabetes patients are on FDC of three drugs? *

  20. In your 100 Diabetic patients, what% of patients, you would like to recommend below class of new OAD FDC? (Sum total of response should be 100%)*
    21. SU+ Metformin + DPP4i
    SU+ Metformin + SGLT2i
    DPP4i+ SGLT2i + Metformin
  21. Amongst the FDCs of SGLT2i + DPP4i + MET which of the following distinguishing parameters do you find most attractive ? (Tick any one) *

  22. How likely would you prescribe FDC of Sitagliptin + Glimepiride + Metformin once available? *

    23. Not at all LikelyExtremely likely

  23. What would be your reason for prescribing FDC of Sitalgiptin + Glimepiride + Metformin? (Tick any one) *